FdaApplication
NDA 021275
Identifiers
- fda_app_no: NDA021275
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2001-03-16 |
Revenue by product
LUMIGAN
| Period | Revenue |
|---|---|
| Q4 2025 | $104.0M |
| Q3 2025 | $97.0M |
| Q2 2025 | $103.0M |
| Q1 2025 | $106.0M |
| Q4 2024 | $119.0M |
| Q3 2024 | $116.0M |
| Q2 2024 | $103.0M |
| Q1 2024 | $91.0M |
| Q4 2023 | $92.0M |
| Q3 2023 | $91.0M |
| Q2 2023 | $119.0M |
| Q1 2023 | $130.0M |
| Q4 2022 | $123.0M |
| Q3 2022 | $121.0M |
| Q2 2022 | $130.0M |
| Q1 2022 | $140.0M |
| Q4 2021 | $149.0M |
| Q3 2021 | $138.0M |
| Q2 2021 | $149.0M |
| Q1 2021 | $143.0M |
| Q4 2020 | $153.0M |
| Q3 2020 | $149.0M |
| Q2 2020 | $76.0M |
| Q1 2020 | $0.0M |
| Q4 2019 | $0.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LUMIGAN | BIMATOPROST | 0.03% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION/DROPS;OPHTHALMIC |
1 product